Prof. Jilong Yang 杨吉龙
Chief Physician, Professor
Department of Bone and Soft Tissue Tumors, Tianjin Medical University Cancer Institute & Hospital, Tianjin
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Comprehensive treatment of bone and soft tissue sarcomas, with a focus on surgery. Surgical and comprehensive treatment of malignant melanoma.
Dr. Yang holds a PhD and serves as Professor, Chief Physician, and Deputy Department Director. A doctoral supervisor, Dr. Yang was selected for Tianjin Medical University’s “11th Five-Year New Century Talent” program, Tianjin universities’ “Young and Middle-aged Backbone Innovative Talent Training Plan,” and Tianjin’s “131” Innovative Talent program. In 2010, Dr. Yang received the “National Health System Young Post Expert” award.
Professional roles
- Member, Chinese Medical Association
- Deputy Leader, Soft Tissue Sarcoma Group, Sarcoma Professional Committee, China Anti-Cancer Association
- Youth Committee Member, Oncology Branch, Chinese Medical Association
Name order: in Chinese the family name comes first (Yang Jilong). Papers usually list the name as Jilong Yang or Yang J.
Selected publications
78 papers on PubMed matched by name and affiliation; 41 as first or senior author since 2016. Most recent first- or senior-author papers:
- Transl Cancer Res, 2026 (senior author): Targeting miR-506 in leiomyosarcoma therapy: simultaneous suppression of metastatic potential and potentiation of pirarubicin efficacy. PubMed 42997687
- Front Oncol, 2026 (senior author): Clinical characteristics and immunotherapy in Chinese patients with Merkel cell carcinoma: a retrospective analysis. PubMed 42839999
- Front Immunol, 2026 (senior author): Immunotherapy-based salvage therapy in advanced soft tissue sarcoma after first-line chemotherapy: a retrospective single-center analysis with emphasis on undifferentiated pleomorphic sarcoma. PubMed 42723918
- Adv Sci (Weinh), 2026 (senior author): Genome-Wide CRISPR Screen Identifies a microRNA Orchestrating Pleiotropic Resistance to Targeted Therapy and T Cell Immunity in Melanoma. PubMed 42189126
- Adv Sci (Weinh), 2026 (senior author): Single-Cell Dissection of Tumor-Infiltrating Lymphocytes Reveals Cellular Architecture Predictive of Therapeutic Efficacy in Acral Melanoma. PubMed 41486415
- Expert Opin Ther Targets, 2025 (senior author): Assessing the current molecular understanding of therapeutic targets in osteosarcoma. PubMed 40776443
- Acta Chir Belg, 2024 (senior author): Comparison of short‑term outcomes and 3-year overall survival between robotic and laparoscopic gastrectomy for gastric cancer: a propensity score matching analysis. PubMed 38693890
- Cell Death Discov, 2024 (senior author): The fusion gene LRP1-SNRNP25 drives invasion and migration by activating the pJNK/37LRP/MMP2 signaling pathway in osteosarcoma. PubMed 38678020
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion